Changes in Beneficial Ownership · 4
Sera Prognostics, Inc.
SERANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-10
- Issuer
- SERA PROGNOSTICS, INC.
- Issuer CIK
- 0001534969
- Trading symbol
- SERA
Reporting owner 1
- Name
- Jackson Benjamin
- Reporting owner CIK
- 0001779964
- Relationship
- Officer
- Officer title
- General Counsel
- Address
- C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY, UT, 84109
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | 2026-09-10 | S · Form 4 | 2,190[F1] | D | 2[F2] | 159,566 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person.↩ 1
- F2
- The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $2.00 to $2.03, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.↩ 1
Signature 1
- Signed
- /s/ Benjamin G. Jackson
- Date
- 2026-09-11
Company context
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera’s mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera’s precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City, Utah.